Perspective Therapeutics, Inc. (NYSE:CATX) Receives Consensus Recommendation of "Buy" from Analysts

Key Points

• Analysts give Perspective Therapeutics, Inc. (NYSE:CATX) a consensus rating of "Buy", with an average 12-month target price of $12.56.
• Institutional investors have increased their stakes in the company, with hedge funds owning 54.66% of the stock.
• Despite the positive recommendations, Perspective Therapeutics’ stock is currently down 2.6%, trading at $3.82 per share.

Shares of Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) have received a consensus rating of "Buy" from the eleven research firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and three have given a strong buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $12.5556.

A number of brokerages recently weighed in on CATX. B. Riley reiterated a "buy" rating and set a $12.00 price objective (up previously from $9.00) on shares of Perspective Therapeutics in a report on Monday, June 23rd. Royal Bank Of Canada raised shares of Perspective Therapeutics from an "outperform" rating to a "moderate buy" rating and increased their price target for the company from $15.00 to $16.00 in a research report on Tuesday, June 3rd. Wedbush restated an "outperform" rating and set a $11.00 price target on shares of Perspective Therapeutics in a research note on Monday, June 23rd. Truist Financial cut their target price on Perspective Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Finally, Lifesci Capital raised shares of Perspective Therapeutics to a "strong-buy" rating in a research report on Saturday, July 12th.

Institutional Investors Weigh In On Perspective Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Millennium Management LLC acquired a new position in Perspective Therapeutics during the fourth quarter worth approximately $4,132,000. Two Sigma Advisers LP acquired a new stake in Perspective Therapeutics in the fourth quarter valued at approximately $484,000. JPMorgan Chase & Co. lifted its holdings in Perspective Therapeutics by 498.3% in the 4th quarter. JPMorgan Chase & Co. now owns 149,045 shares of the company's stock worth $475,000 after buying an additional 124,133 shares in the last quarter. Two Sigma Investments LP acquired a new stake in Perspective Therapeutics during the 4th quarter valued at approximately $2,075,000. Finally, Jump Financial LLC acquired a new stake in Perspective Therapeutics in the fourth quarter valued at $688,000. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Perspective Therapeutics Stock Down 2.6%

NYSE CATX opened at $3.82 on Thursday. Perspective Therapeutics has a 52 week low of $1.60 and a 52 week high of $16.55. The company has a fifty day moving average of $3.62 and a two-hundred day moving average of $2.96.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.